TESARO Inc to Post FY2021 Earnings of ($2.99) Per Share, Leerink Swann Forecasts (TSRO)

Share on StockTwits

TESARO Inc (NASDAQ:TSRO) – Investment analysts at Leerink Swann issued their FY2021 earnings per share estimates for TESARO in a report issued on Tuesday, October 16th. Leerink Swann analyst A. Berens anticipates that the biopharmaceutical company will post earnings of ($2.99) per share for the year. Leerink Swann currently has a “Outperform” rating and a $48.00 price target on the stock. Leerink Swann also issued estimates for TESARO’s FY2022 earnings at ($0.09) EPS.

TSRO has been the topic of several other research reports. Cann reaffirmed a “buy” rating and issued a $83.00 price target on shares of TESARO in a research report on Tuesday, September 4th. HC Wainwright dropped their price target on shares of TESARO to $71.00 and set a “buy” rating on the stock in a research report on Friday, July 20th. Zacks Investment Research raised shares of TESARO from a “sell” rating to a “hold” rating in a research report on Tuesday, July 17th. Guggenheim started coverage on shares of TESARO in a research report on Monday, September 17th. They issued a “buy” rating on the stock. Finally, BidaskClub raised shares of TESARO from a “hold” rating to a “buy” rating in a research report on Friday, October 5th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $78.42.

Shares of NASDAQ TSRO opened at $41.75 on Thursday. TESARO has a fifty-two week low of $25.62 and a fifty-two week high of $119.00. The stock has a market capitalization of $2.43 billion, a P/E ratio of -4.55 and a beta of 1.01. The company has a current ratio of 4.11, a quick ratio of 3.64 and a debt-to-equity ratio of -29.71.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.66) by ($0.38). TESARO had a negative net margin of 180.29% and a negative return on equity of 285.30%. The business had revenue of $57.21 million during the quarter, compared to the consensus estimate of $65.50 million. During the same period in the previous year, the business posted ($2.82) EPS. TESARO’s revenue was up 94.2% compared to the same quarter last year.

Several institutional investors have recently bought and sold shares of TSRO. Skylands Capital LLC bought a new position in shares of TESARO during the 2nd quarter worth approximately $182,000. New Jersey Better Educational Savings Trust bought a new position in shares of TESARO during the 3rd quarter worth approximately $234,000. Stifel Financial Corp bought a new position in shares of TESARO during the 1st quarter worth approximately $241,000. Janney Montgomery Scott LLC bought a new position in shares of TESARO during the 2nd quarter worth approximately $257,000. Finally, BTG Pactual Global Asset Management Ltd bought a new position in shares of TESARO during the 2nd quarter worth approximately $277,000.

In other TESARO news, Director Arnold L. Oronsky sold 10,000 shares of TESARO stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $26.77, for a total transaction of $267,700.00. Following the transaction, the director now owns 12,479 shares of the company’s stock, valued at approximately $334,062.83. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders have sold 10,630 shares of company stock worth $290,424. Insiders own 33.70% of the company’s stock.

TESARO Company Profile

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Article: Yield Curve

Earnings History and Estimates for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

US Concrete  Upgraded to “Hold” by ValuEngine
US Concrete Upgraded to “Hold” by ValuEngine
Coherent  Downgraded by BidaskClub to “Sell”
Coherent Downgraded by BidaskClub to “Sell”
Ebix  Upgraded to Sell by BidaskClub
Ebix Upgraded to Sell by BidaskClub
Capital Bank & Trust Co Sells 1,165 Shares of Cerner Co.
Capital Bank & Trust Co Sells 1,165 Shares of Cerner Co.
$1.54 EPS Expected for Crane Co.  This Quarter
$1.54 EPS Expected for Crane Co. This Quarter
Capital Bank & Trust Co Increases Stake in Prologis Inc
Capital Bank & Trust Co Increases Stake in Prologis Inc


© 2006-2018 Ticker Report